Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mark Vickery headshot

June PPI Weak at -0.2%, COVID Drug Adds Promise

by Mark Vickery

June Producer Price Index headline of -0.2% was a big miss from the +0.4% consensus and the +0.4% headline for May.

Gilead Starts Testing Remdesivir Inhaled Version for Coronavirus

by Zacks Equity Research

Gilead (GILD) begins a phase I study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir for coronavirus.

Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Regeneron Initiates Studies on Experimental Coronavirus Drug

by Zacks Equity Research

Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

Gilead Sciences (GILD) Stock Moves -0.44%: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.

Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.

Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners

by Zacks Equity Research

Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners

Swayta Shah headshot

5 High Dividend-Yielding S&P 500 Stocks Amid Coronavirus Woes

by Swayta Shah

At a time when the coronavirus outbreak has hampered steady stream of income for many, investing in high dividend-yielding stocks can be rewarding. We have picked 5 S&P 500 stocks worth considering.

Ritujay Ghosh headshot

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

by Ritujay Ghosh

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

5 High Earnings Yield Stocks for a Winning Portfolio

by Zacks Equity Research

Earnings yield is very important in comparing a stock with other stocks and with fixed income securities. A stock with higher earnings yield fetches better returns.

Gilead's Coronavirus Drug Gets Conditional Approval in Europe

by Zacks Equity Research

Gilead (GILD) gets conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection by the European Commission.

Gilead's Coronavirus Drug Being Stocked by the US Government

by Zacks Equity Research

Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.

Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More

by Zacks Equity Research

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.

Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial

by Zacks Equity Research

Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $74.56, marking a -0.01% move from the previous day.

GILD vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Mark Vickery headshot

The Final Chapter of Chesapeake Energy Story?

by Mark Vickery

Finding difficulties in dealing with its now $10 billion in debt, fracking pioneer Chesapeake Energy (CHK) has announced it is filing for Chapter 11 bankruptcy protection.

Chesapeake Energy Files Chapter 11

by Zacks Equity Research

Chesapeake Energy Files Chapter 11

Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation

by Zacks Equity Research

Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.

Ritujay Ghosh headshot

3 Stocks to Buy as Companies Speed Up Vaccine Production

by Ritujay Ghosh

Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.

Neena Mishra headshot

Invest in the Future With Megatrend ETFs

by Neena Mishra

These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.

Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III

by Zacks Equity Research

Alexion's (ALXN) subcutaneous formulation of Ultomiris meets primary objective in a late-stage study.

Gilead to Buy 49.9% Stake in Private Biotech for $275M

by Zacks Equity Research

Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (GILD) Outperforming Other Medical Stocks This Year?

Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.